Skip to main content

Table 6 Association between cardiovascular comorbidities and use of biologicals, in particular those of the anti-TNF class

From: Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study

 

Biologicals

Anti-TNF

Yes n*(%)

PRˆ (IC95%)

p

Yes n*(%)

PRˆ (IC95%)

p

Cardiovascular Comorbidities

Yes

276 (69.3)

1.147 (1.050–1.253)

0.003

148 (66.7)

1.060 (0.954–1.179)

0.292

No

122 (30.7)

0.775 (0.652–0.922)

74 (33.3)

0.898 (0.731–1.101)

Systemic Arterial Hypertension

Yes

219 (55)

1.169 (1.039–1.315)

0.011

116 (52.3)

1.059 (0.919–1.221)

0.436

No

179 (45)

0.850 (0.747–0.967)

106 (47.7)

0.942 (0.808–1.097)

Dyslipidemia

Yes

144 (36.2)

1.186 (1.000–1.407)

0.052

80 (36)

1.138 (0.932–1.390)

0.212

No

254 (63.8)

0.918 (0.841–1.003)

142 (64)

0.936 (0.840–1.043)

Diabetes Mellitus

Yes

65 (16.3)

1.161 (0.872–1.546)

0.308

31 (14)

0.925 (0.644–1.328)

0.670

No

333 (83.7)

0.974 (0.924–1.020)

191 (86)

1.013 (0.955–1.076)

Congestive Heart Failure

Yes

10 (2.5)

1.289 (0.578–2.874)

0.535

3 (1.4)

0.575 (0.173–1.911)

0.448

No

388 (97.5)

0.994 (0.976–1.013)

219 (98.6)

1.010 (0.992–1.029)

Cerebrovascular Disease

Yes

4 (1)

0.361 (0.124–1.048)

0.054

1 (0.5)

0.175 (0.024–1.289)

0.066

No

394 (99)

1.018 (1.002–1.035)

222 (99.5)

1.022 (1.008–1.036)

Acute Myocardial Infarction

Yes

12 (3)

4.330 (1.536–12.201)

0.002

3 (1.4)

0.863 (0.250–2.977)

1.000

No

386 (97)

0.977 (0.959–0.995)

219 (98.6)

1.002 (0.985–1.020)

Peripheral Vascular Disease

Yes

3 (0.8)

1.082 (0.260–4.505)

1.000

1 (0.5)

0.575 (0.071–4.652)

1.000

No

395 (99.2)

0.999 (0.989–1.010)

221 (99.5)

1.003 (0.993–1.014)

  1. *Absolute frequencies; ˆ Prevalence Ratio Significance level